Literature DB >> 18457727

[Imatinib-induced DRESS].

J Goldman1, A-B Duval-Modeste, A Lambert, N Contentin, P Courville, P Musette, P Joly.   

Abstract

BACKGROUND: Imatinib (Glivec) is a tyrosine kinase inhibitor used to treat certain cases of leukaemia. We report a case of a drug-induced reaction with eosinophilia and systemic symptoms (DRESS) caused by imatinib. CASE-REPORT: A 77-year-old woman with a chronic myeloid leukaemia was treated with imatinib and allopurinol. Nineteen days after the start of treatment, the patient presented fever with a generalized polymorphous rash associated with oral erosions, facial oedema, diffuse lymphadenopathy and blood hypereosinophilia. Histological analysis of skin biopsy specimens suggested a drug-induced reaction. The outcome was favourable two weeks after discontinuation of treatment. Three months later, imatinib was reintroduced because of progression of the patient's chronic myeloid leukaemia, and recurrence of the skin rash and fever was observed within 12 hours. DISCUSSION: Allopurinol was stopped definitively because of its more frequent imputability. Imatinib was reintroduced after considering the benefit-risk ratio and in full knowledge of the existence of cutaneous reactions to imatinib, despite there being only one recent report of DRESS following treatment with imatinib. According to the causality criteria of Bégaud et al. regarding imatinib, inherent causality of the drug in our patient was initially possible (I2) and appeared likely (I3) after the rechallenge test. This case clearly illustrates that imatinib is a potential cause of DRESS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18457727     DOI: 10.1016/j.annder.2007.10.007

Source DB:  PubMed          Journal:  Ann Dermatol Venereol        ISSN: 0151-9638            Impact factor:   0.777


  6 in total

1.  Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitors.

Authors:  Emmanuelle Faye; Emmanuelle Bondon-Guitton; Pascale Olivier-Abbal; Jean-Louis Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2013-06-09       Impact factor: 2.953

Review 2.  Characterizing DRESS syndrome recurrence: a systematic review.

Authors:  Ajay N Sharma; Samantha Shwe; Vignesh Ravi; Melanie Miller; Natasha A Mesinkovska; Nathan W Rojek; Scott Worswick
Journal:  Arch Dermatol Res       Date:  2021-09-10       Impact factor: 3.033

Review 3.  Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review).

Authors:  Emily L Coleman; Brianna Olamiju; Jonathan S Leventhal
Journal:  Oncol Rep       Date:  2020-12-24       Impact factor: 3.906

4.  Chronic myeloid leukaemia and human immunodeficiency virus (HIV) infection.

Authors:  Michael J Webb; Claire L Barrett; Christel Pretorius; Magdalena F van Jaarsveld; Vernon J Louw
Journal:  Int J Hematol       Date:  2012-04-20       Impact factor: 2.319

Review 5.  Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies.

Authors:  Chun-Bing Chen; Ming-Ying Wu; Chau Yee Ng; Chun-Wei Lu; Jennifer Wu; Pei-Han Kao; Chan-Keng Yang; Meng-Ting Peng; Chen-Yang Huang; Wen-Cheng Chang; Rosaline Chung-Yee Hui; Chih-Hsun Yang; Shun-Fa Yang; Wen-Hung Chung; Shih-Chi Su
Journal:  Cancer Manag Res       Date:  2018-05-17       Impact factor: 3.989

6.  Successful Treatment of Imatinib-Induced DRESS Syndrome Using Reslizumab without Cessation of Imatinib: A Case Report.

Authors:  Hyerin Park; Gil-Soon Choi; Eun Mi Lee
Journal:  Case Rep Oncol       Date:  2021-10-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.